WO2007072503A3 - Combinations for managing inflammation and associated disorders - Google Patents

Combinations for managing inflammation and associated disorders Download PDF

Info

Publication number
WO2007072503A3
WO2007072503A3 PCT/IN2006/000496 IN2006000496W WO2007072503A3 WO 2007072503 A3 WO2007072503 A3 WO 2007072503A3 IN 2006000496 W IN2006000496 W IN 2006000496W WO 2007072503 A3 WO2007072503 A3 WO 2007072503A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated disorders
combinations
inflammation
compositions
managing inflammation
Prior art date
Application number
PCT/IN2006/000496
Other languages
French (fr)
Other versions
WO2007072503A2 (en
Inventor
Rajesh Jain
Kour Chand Jindal
Original Assignee
Panacea Biotec Ltd
Rajesh Jain
Kour Chand Jindal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd, Rajesh Jain, Kour Chand Jindal filed Critical Panacea Biotec Ltd
Publication of WO2007072503A2 publication Critical patent/WO2007072503A2/en
Publication of WO2007072503A3 publication Critical patent/WO2007072503A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Pharmaceutical compositions comprising at least one analgesic and anti-inflammatory compound(s) that inhibits both cyclooxygenase (COX) and lipooxygenase (LOX) as active agent in combination with at least one another active agent(s) optionally with other pharmaceutically, acceptable excipients is provided. Also described are process for preparation of such compositions and method of using such compositions for the management of inflammation and pain and/or other associated disorders.
PCT/IN2006/000496 2005-12-21 2006-12-18 Combinations for managing inflammation and associated disorders WO2007072503A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3431DE2005 2005-12-21
IN3431/DEL/2005 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007072503A2 WO2007072503A2 (en) 2007-06-28
WO2007072503A3 true WO2007072503A3 (en) 2007-11-01

Family

ID=38006815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000496 WO2007072503A2 (en) 2005-12-21 2006-12-18 Combinations for managing inflammation and associated disorders

Country Status (1)

Country Link
WO (1) WO2007072503A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
TR200708925A1 (en) * 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Combinations of flurbiprofen and muscle relaxants for controlled release
WO2010038240A1 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical composition comprising nimesulide and levocetirizine
KR20100060189A (en) * 2008-11-27 2010-06-07 국립암센터 A pharmaceutical composition for preventing or treating transglutaminase-related disease comprising ethacrynic acid, and a method for preventing or treating transglutaminase-related disease by using thereof
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US20120244221A1 (en) 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US8236857B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120237574A1 (en) 2010-07-08 2012-09-20 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
JP2015503583A (en) * 2012-01-04 2015-02-02 ウェルズリー ファーマスーティカルズ、エルエルシー Extended release formulation for reducing urination frequency and method of use thereof
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
CA2856673C (en) * 2012-01-04 2018-08-21 Wellesley Pharmaceuticals, Llc Use of acetaminophen for reducing the frequency of urination
AU2013252491A1 (en) * 2012-04-27 2014-11-06 Troy Laboratories Pty Ltd Combination meloxicam and xylazine therapy in animals
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
JP2016518388A (en) 2013-04-30 2016-06-23 オティトピック インク． Dry powder formulation and usage
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
MX348595B (en) 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Pharmaceutical composition with anti-inflammatory agents and production process thereof.
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
PL2848261T3 (en) 2013-09-12 2016-10-31 Pharmaceutical formulations comprising a muscle relaxant and an analgesic combination
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
JP6371463B2 (en) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Immediate release abuse deterrent liquid filler form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10206904B2 (en) 2015-07-17 2019-02-19 The Board Of Regents Of The University Of Oklahoma Licofelone derivatives and methods of use
BR112019005224A2 (en) 2016-09-26 2019-06-11 Procter & Gamble dosage form for prolonged relief
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US10195147B1 (en) 2017-09-22 2019-02-05 Otitopic Inc. Dry powder compositions with magnesium stearate
US20210228598A1 (en) * 2018-08-13 2021-07-29 Federico Amezcua Amezcua Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses
CN108703953A (en) * 2018-08-27 2018-10-26 海南皇隆制药股份有限公司 A kind of injection benzene sulphur is along atracurium freeze drying powder injection and preparation method thereof
MX2019000312A (en) * 2019-01-08 2019-10-09 Federico Amezcua Amezcua A synergistic pharmaceutical composition of aceclofenac and betamethasone for the treatment of pain of rheumatic affections or post-surgical pain.
WO2020215057A1 (en) * 2019-04-18 2020-10-22 The Regents Of The University Of California Pharmacological mitigation of late-stage toxemia
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
KR20230051164A (en) 2020-07-15 2023-04-17 샤바르 리서치 어소시에이츠 엘엘씨 Oral unit dosage composition consisting of ibuprofen and famotidine for treatment of acute pain and reduction of severity and/or risk of heartburn

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652255A (en) * 1994-03-07 1997-07-29 British Technology Group Limited Potentiation of bioreductive agents
WO2003097041A1 (en) * 2002-05-17 2003-11-27 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
WO2004058240A1 (en) * 2002-12-19 2004-07-15 Insmed Incorporated Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US20040259920A1 (en) * 2001-04-30 2004-12-23 Zouboulis Christos C. Acne treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652255A (en) * 1994-03-07 1997-07-29 British Technology Group Limited Potentiation of bioreductive agents
US20040259920A1 (en) * 2001-04-30 2004-12-23 Zouboulis Christos C. Acne treatment
WO2003097041A1 (en) * 2002-05-17 2003-11-27 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
WO2004058240A1 (en) * 2002-12-19 2004-07-15 Insmed Incorporated Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BETHEL R A ET AL: "CYCLOOXYGENASE INHIBITORS INCREASE CANINE TRACHEAL MUSCLE RESPONSE TO PARASYMPATHETIC STIMULI IN-SITU", JOURNAL OF APPLIED PHYSIOLOGY, vol. 68, no. 6, 1990, pages 2597 - 2603, XP009085242, ISSN: 8750-7587 *
BRUNE K: "SAFETY OF ANTI-INFLAMMATORY TREATMENT-NEW WAYS OF THINKING", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 43, no. SUPPL 1, February 2004 (2004-02-01), pages I16 - I20, XP008042111, ISSN: 1462-0324 *
CHARLIER C ET AL: "Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 7-8, July 2003 (2003-07-01), pages 645 - 659, XP004448316, ISSN: 0223-5234 *
DARIUS H ET AL: "INHIBITION OF THE PLATELET ACTIVATING FACTOR MEDIATED COMPONENT OF GUINEA-PIG ANAPHYLAXIS BY RECEPTOR ANTAGONISTS", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, vol. 80, no. 4, 1986, pages 369 - 375, XP009085245, ISSN: 0020-5915 *
ISSEKUTZ A C ET AL: "SYNERGISTIC INHIBITION OF COMPLEMENT INDUCED GRANULOCYTE MARGINATION BY BW-755C AND CALCIUM CHANNEL BLOCKERS", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 7, no. 6, 1985, pages 791 - 800, XP002437814, ISSN: 0192-0561 *
MAULIK M ET AL: "Effects of supplementation with iloprost on the cardioprotection by BW755C (a dual inhibitor of cyclooxygenase and lipoxygenase enzymes) in myocardial reperfusion injury.", PHARMACOLOGICAL RESEARCH, vol. 36, no. 2, August 1997 (1997-08-01), pages 103 - 108, XP002437813, ISSN: 1043-6618 *
SEN T ET AL: "GLUCOSE OXIDASE-INDUCED LYSIS OF ERYTHROCYTES", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 33, no. 1, January 1995 (1995-01-01), pages 75 - 76, XP009026651, ISSN: 0019-5189 *
WIKLUND N P ET AL: "Endothelin modulation of neuroeffector transmission in rat and guinea pig vas deferens.", EUROPEAN JOURNAL OF PHARMACOLOGY 21 AUG 1990, vol. 185, no. 1, 21 August 1990 (1990-08-21), pages 25 - 33, XP002438621, ISSN: 0014-2999 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US9527858B2 (en) 2009-07-16 2016-12-27 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Also Published As

Publication number Publication date
WO2007072503A2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2007072503A3 (en) Combinations for managing inflammation and associated disorders
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
CA2477301A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
WO2008146178A3 (en) A novel tablet dosage form
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
MX2009004203A (en) Acetaminophen / ibuprofen combinations.
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2006053160A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2005123192A3 (en) Improving pain treatment with strontium combinations
IL178591A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for the treatment and management of myelodysplastic syndromes
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
EP1774968A4 (en) Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
CA2668320A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2006110473A3 (en) Phospholipid-based pharmaceutical formulations and methods for producing and using same
AR051589A1 (en) THERAPEUTIC AGENTS
MY160002A (en) Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
WO2006050057A3 (en) Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
WO2007010501A3 (en) A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
EA200702386A1 (en) SOLID PHARMACEUTICAL COMPOSITION FOR LONG-TERM EXEMPTION OF 1- (2,3,4-TRIMETOXIBENZYL) PIPERAZINE AND METHOD FOR ITS PREPARATION
WO2001045683A3 (en) Formulations of adenosine a1 agonists
JP2008540603A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06842774

Country of ref document: EP

Kind code of ref document: A2